Literature DB >> 19870978

TYPE-SPECIFIC ANTIGENS, M AND T, OF MATT AND GLOSSY VARIANTS OF GROUP A HEMOLYTIC STREPTOCOCCI.

R C Lancefield1.   

Abstract

1. Two qualitatively different type-specific antigens, designated M and T, have been found present in matt variants of group A hemolytic streptococci, but only one of these, the T antigen, occurs in the degraded glossy variant. 2. The protein nature of the M antigen, present in matt variants only, has been demonstrated in previous work, but the chemical characteristics of the newly recognized antigenic factor, T, present in both variants, have not been determined. This T factor is identified only by its immunological reactions. It is unknown whether the two type-specific antigenic factors, M and T, occur as separate chemical entities in the matt variant or in conjugation. 3. Antibody to the type-specific protein, M, appears responsible for the M precipitin reaction, for type-specific protection, and, as a rule, for part of the type-specific agglutination of matt variants, but in type 1 it does not cause agglutination. 4. Antibody to the second type-specific antigen, T, seems to be solely responsible for type-specific agglutination of the glossy form and to play a large rôle in type-specific agglutination of the matt form, but apparently it is not involved in protection. This T antibody causes all of the type-specific agglutination of type 1. Consequently, type 1 matt and glossy variants agglutinate and absorb agglutinin alike, and antisera to both are identical in content of type-specific agglutinin though they differ in respect to M antibody. 5. Recognition of the principle underlying type-specific agglutination of glossy variants makes it possible to suggest, with certain reservations, the use of glossy variants for type classification by agglutination. These variants are suitable for preparing type-specific agglutinating antisera, and they form stable suspensions for use in the reaction. Improved methods are needed for deriving glossy from matt variants.

Year:  1940        PMID: 19870978      PMCID: PMC2135088          DOI: 10.1084/jem.71.4.521

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  8 in total

1.  STUDIES ON THE BIOLOGY OF STREPTOCOCCUS : I. ANTIGENIC RELATIONSHIPS BETWEEN STRAINS OF STREPTOCOCCUS HAEMOLYTICUS.

Authors:  A R Dochez; O T Avery; R C Lancefield
Journal:  J Exp Med       Date:  1919-09-01       Impact factor: 14.307

2.  VARIANTS OF HEMOLYTIC STREPTOCOCCI; THEIR RELATION TO TYPE-SPECIFIC SUBSTANCE, VIRULENCE, AND TOXIN.

Authors:  E W Todd; R C Lancefield
Journal:  J Exp Med       Date:  1928-11-30       Impact factor: 14.307

3.  ANTIGENIC PROPERTIES OF THE TYPE-SPECIFIC SUBSTANCE DERIVED FROM GROUP A HEMOLYTIC STREPTOCOCCI.

Authors:  G K Hirst; R C Lancefield
Journal:  J Exp Med       Date:  1939-02-28       Impact factor: 14.307

4.  PROTEIN FRACTIONS OF A SCARLATINAL STRAIN OF STREPTOCOCCUS HEMOLYTICUS.

Authors:  M Heidelberger; F E Kendall
Journal:  J Exp Med       Date:  1931-09-30       Impact factor: 14.307

5.  TWO SEROLOGICAL TYPES OF GROUP B HEMOLYTIC STREPTOCOCCI WITH RELATED, BUT NOT IDENTICAL, TYPE-SPECIFIC SUBSTANCES.

Authors:  R C Lancefield
Journal:  J Exp Med       Date:  1938-01-01       Impact factor: 14.307

6.  THE ANTIGENIC COMPLEX OF STREPTOCOCCUS HAEMOLYTICUS : II. CHEMICAL AND IMMUNOLOGICAL PROPERTIES OF THE PROTEIN FRACTIONS.

Authors:  R C Lancefield
Journal:  J Exp Med       Date:  1928-02-29       Impact factor: 14.307

7.  STUDIES ON THE HEMOLYTIC STREPTOCOCCUS OF HUMAN ORIGIN : II. OBSERVATIONS ON THE PROTECTIVE MECHANISM AGAINST THE VIRULENT VARIANTS.

Authors:  C Lyons; H K Ward
Journal:  J Exp Med       Date:  1935-03-31       Impact factor: 14.307

8.  ANTIGENIC DIFFERENCES BETWEEN MATT HEMOLYTIC STREPTOCOCCI AND THEIR GLOSSY VARIANTS.

Authors:  R C Lancefield; E W Todd
Journal:  J Exp Med       Date:  1928-11-30       Impact factor: 14.307

  8 in total
  23 in total

1.  [Typing of hemolytic streptococci by the agglutination test].

Authors:  G OBIGER
Journal:  Z Hyg Infektionskr       Date:  1959

2.  [Virulence of A-Streptococci during various phases of growth].

Authors:  E VON WASIELEWSKI; E HERMANN
Journal:  Z Hyg Infektionskr       Date:  1957

3.  Identification of group A streptococcal emm types commonly associated with invasive infections and antimicrobial resistance by the use of multiplex PCR and high-resolution melting analysis.

Authors:  P Bidet; S Liguori; C Plainvert; S Bonacorsi; C Courroux; C d'Humières; C Poyart; A Efstratiou; E Bingen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-20       Impact factor: 3.267

4.  Capsular Polysaccharide of Group A Streptococcus.

Authors:  Michael R Wessels
Journal:  Microbiol Spectr       Date:  2019-01

5.  Preparation and properties of type-specific M antigen isolated from a group A, type 1 hemolytic streptococcus.

Authors:  R C LANCEFIELD; G E PERLMANN
Journal:  J Exp Med       Date:  1952-07       Impact factor: 14.307

6.  The relative importance of the capsule and the M-antigen in determining colony form of group A streptococci.

Authors:  A T WILSON
Journal:  J Exp Med       Date:  1959-03-01       Impact factor: 14.307

7.  THE ROLE OF THE MUCOID POLYSACCHARIDE (HYALURONIC ACID) IN THE VIRULENCE OF GROUP A HEMOLYTIC STREPTOCOCCI.

Authors:  E H Kass; C V Seastone
Journal:  J Exp Med       Date:  1944-03-01       Impact factor: 14.307

8.  Size variation of the M protein in group A streptococci.

Authors:  V A Fischetti; K F Jones; J R Scott
Journal:  J Exp Med       Date:  1985-06-01       Impact factor: 14.307

9.  THE SIGNIFICANCE OF M AND T ANTIGENS IN THE CROSS REACTIONS BETWEEN CERTAIN TYPES OF GROUP A HEMOLYTIC STREPTOCOCCI.

Authors:  R C Lancefield
Journal:  J Exp Med       Date:  1940-03-31       Impact factor: 14.307

10.  STUDIES ON THE ANTIGENIC COMPOSITION OF GROUP A HEMOLYTIC STREPTOCOCCI : I. EFFECTS OF PROTEOLYTIC ENZYMES ON STREPTOCOCCAL CELLS.

Authors:  R C Lancefield
Journal:  J Exp Med       Date:  1943-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.